Rewind Therapeutics raises additional financing for oral remyelination program

On October 6, 2026, Rewind Therapeutics announced it had secured additional financing to advance its oral GPR17 antagonist program for remyelination in multiple sclerosis. The announcement did not specify the amount or investors in the available report.

The funding is intended to support key studies needed before clinical testing (IND-enabling studies) and move the program toward the clinic.

The news follows a July 2026 peer-reviewed PLOS ONE study. In animal models of demyelination, once-daily oral treatment with the selective GPR17 antagonist RWT020016 accelerated remyelination and improved measures including visual nerve signaling and spatial memory.

These are preclinical findings, not evidence of benefit in people. Rewind’s approach aims to repair myelin, unlike treatments that primarily control inflammation.